You are here

Cerner to Release Third Quarter 2018 Earnings Results October 25

KANSAS CITY, Mo., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Cerner Corporation (Nasdaq: CERN) today announced it will release its third quarter 2018 earnings results after the market closes Thursday, Oct. 25. Following the release, the company will hold a conference call at 3:30 p.m. CT that can be accessed via dial-in or webcast. On the call, Cerner will discuss its results and outlook and answer questions from the investment community. The call may also include discussion of Cerner developments and other material and forward-looking information about business and financial matters.

The dial-in number for the conference call is (678) 509-7542; the passcode is Cerner. The company recommends joining the call 15 minutes early for registration. The rebroadcast of the call will be available from 6:30 p.m. CT, Thursday, October 25, through 10:59 p.m. CT, Sunday, October 28. The dial-in number for the rebroadcast is (855) 859-2056; the passcode is 1497566.

An audio webcast will be available live and archived on Cerner’s website in the Investor Relations section.

About Cerner
Cerner’s health technologies connect people and information systems at more than 27,500 contracted provider facilities worldwide dedicated to creating smarter and better care for individuals and communities. Recognized globally for innovation, Cerner assists clinicians in making care decisions and assists organizations in managing the health of their populations. The company also offers an integrated clinical and financial system to help manage day-to-day revenue functions, as well as a wide range of services to support clinical, financial and operational needs, focused on people. For more information, visit Cerner.comThe Cerner Blog or connect on FacebookInstagram, LinkedInTwitter or The Cerner Podcast. Nasdaq: CERN. Smarter Care. Better Outcomes. Healthier You.

Media Contact: Misti Preston, Public Relations, (816) 299-2037
Investor Contact: Allan Kells, Investor Relations, (816) 201-2445

Thursday, October 11, 2018 - 08:30

More Headlines

Resorbable Dextenza is the First Intracanalicular Insert for Drug Delivery
Patients with MS Suffered Stroke, Blood Vessel Tearing in Head and Neck After Receiving Drug
First Biosimilar For Adults With CD20-Positive, B-Cell Non-Hodgkin’s Lymphoma
Life-Threatening Side Effect of Drug for Acute Myeloid Leukemia
First Drug for Rare Autoimmune Disorder That Affects Nerve, Muscles Connection
Hope For Patients With Highly Aggressive Form of AML
Oncology Therapy for Adult and Pediatric Tumors With a Neurotrophic Receptor Tyrosine Kinase (NTRK) Gene Fusion
First Hedgehog Pathway Inhibitor Approved for AML in Adults Aged 75 and Older
Gene Therapy Granted Regenerative Medicine, Fast Track Designations